Tolvaptan

Tolvaptan is a selective, competitive and orally active vasopressin receptor 2 (V2R) antagonist with an IC50 of 1.28 μM for the inhibition of arginine vasopressin (AVP) -induced platelet aggregation. Tolvaptan induces cell apoposis and affects cell cycle. Tolvaptan can be used for the research of hyponatremia[1][2].

Product Specifications

CAS Number

[150683-30-0]

Product Name Alternative

OPC-41061

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Autophagy; Vasopressin Receptor

Type

Reference compound

Related Pathways

Autophagy; GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Cardiovascular Disease; Endocrinology; Cancer

Assay Protocol

https://www.medchemexpress.com/Tolvaptan.html

Purity

99.95

Solubility

DMSO : ≥ 100 mg/mL

Smiles

O=C(C1=CC=CC=C1C)NC2=CC=C(C(C)=C2)C(N3CCCC(C4=CC(Cl)=CC=C43)O)=O

Molecular Formula

C26H25ClN2O3

Molecular Weight

448.94

Precautions

H302, H315, H319, H335

References & Citations

[1]Wu Y, et al. Mechanisms of tolvaptan-induced toxicity in HepG2 cells. Biochem Pharmacol. 2015 Jun 15;95 (4) :324-36.|[2]El-Shabrawy M, et al. Protective effect of tolvaptan against cyclophosphamide-induced nephrotoxicity in rat models. Pharmacol Res Perspect. 2020 Oct;8 (5) :e00659.